Prize for Diabetology 2021-2022
Novo Nordisk is a global healthcare company, founded in 1923 and headquartered just outside Copenhagen, Denmark.
We employ more than 45,000 people in 80 offices around the world, and market our products in 169 countries.
Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, rare blood and rare endocrine diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat.
Deadline submission final thesis
February 28, 2022
Last quarter of 2022
2012: Prof. Dr. Philips - CHU De Liège
2014: Prof. Dr. Martens - AZ Delta Roeselare
2016: Prof. Dr. De Block - UZ Antwerpen
2018: Prof. Dr. De Leu - UZ Brussel
2020 : Prof. Dr. Benhalima - UZ Leuven